Combe therapy
Paul mentioned a combo approach using their PDC and immunotherapy, the reason is a combination of cytotoxic drugs and immunotherapy seems to have better therapeutic effects.
“In summary, cytotoxic drugs represent useful combination partners for PD-(L)1 immune checkpoint inhibitors and the design of novel drug combinations is essential to augment the success of combined chemo-/immunotherapy. Knowledge gained in this area will aid in the design of more efficient treatments. Given the large diversity of cytotoxic drugs and targeted small molecules, the possibilities of combinations are extremely diversified, as attested by the vast number of ongoing combination trials. We are currently witnessing a revolution in cancer therapy with the advent of immunotherapy targeting PD-(L)1 and other immune checkpoints. To gain the best benefit of these new immuno-drugs, we need to usher in a new conception of the role of cytotoxic chemotherapy in treatment: away from purely cytotoxic molecules that target highly proliferating cells and toward immunomodulators that concur to cripple cancer cells durably. In the near future, it is likely that cytotoxic drugs will continue to play a major role in anticancer therapies, in particular to augment the vulnerability of cancer cells to PD-(L)1 blockade.”
https://academic.oup.com/narcancer/article/2/1/zcaa002/5736808